Crisis in Evergrande and Pfizer outlook - last week's investment results

On December 8, Pfizer announced that a third injection of its vaccine is required to enhance the immune response to the omicron strain of CORONAVIRUS. The announcement helped allay fears that the new strain would be completely resistant to current vaccines, but had little effect on the company's share price, which was only down about 1%.

Pfizer shares have risen in price since the beginning of the pandemic in the US . Compared to the March 2020 low, the shares of the pharmaceutical manufacturer have almost doubled in price.

Now, understanding that a third shot is still needed will not only spur a wave of booster vaccinations, but also increase the likelihood of a special vaccine against a new strain. Pfizer noted that it will be ready by March.

What will happen next

"Pfizer's announcement reinforces our belief that Wall Street is currently underestimating how long the impact of covid-19 drug sales on the company's bottom line will be ," said Cantor Fitzgerald analyst Louise Chen. Efficacy against the omicron strain, along with encouraging data on a new coronavirus-targeted antiviral drug, Paxlovid, adds value to what Chen calls "a best-in-class anti-COVID brand."